News

Parabilis Medicines, Inc., a clinical-stage biopharmaceutical company focused on developing therapies against historically difficult-to-target disease-driving proteins, has successfully…
Read More...

XtalPi has entered into a strategic collaboration with a leading international biopharmaceutical company to develop a next-generation small-molecule therapy targeting a complex G…
Read More...

The United Kingdom has become the first country in Europe to approve Wegovy® pill (semaglutide tablets) for weight management, providing adults living with obesity or overweight a new…
Read More...

DePuy Synthes, a leader in orthopedic technologies and part of Johnson & Johnson MedTech, has announced the U.S. commercial launch of VELYS™ Hip Navigation with AI Assistance, a…
Read More...

Eli Lilly and Company has launched a new national awareness campaign featuring basketball legend Shaquille O’Neal to spotlight moderate-to-severe obstructive sleep apnea (OSA), a common…
Read More...

Bayer has reached an important regulatory milestone for its investigational stroke prevention therapy as the European Medicines Agency (EMA) has validated and begun reviewing the…
Read More...

Beren Therapeutics P.B.C. has raised $300 million in combined financing to support the development and potential commercialization of its investigational therapy adrabetadex, a…
Read More...

GSK has agreed to acquire clinical-stage biotechnology company Nuvalent for approximately $10.6 billion, strengthening its oncology portfolio with a trio of targeted lung cancer…
Read More...

Aditxt, Inc. has announced a definitive business combination agreement that will enable its wholly owned subsidiary, Ignite Proteomics, to become an independent publicly traded company…
Read More...

Eli Lilly and Company has received approval from the U.S. Food and Drug Administration (FDA) for an expanded dosing schedule of EBGLYSS® (lebrikizumab-lbkz), allowing eligible patients…
Read More...

Pfizer has secured an expanded approval from the U.S. Food and Drug Administration (FDA) for HYMPAVZI® (marstacimab-hncq), broadening access to the once-weekly treatment for additional…
Read More...

Johnson & Johnson has agreed to acquire biotechnology company Firefly Bio, Inc. in a deal valued at $1 billion in cash, strengthening its oncology pipeline with a novel platform…
Read More...

Incyte has announced a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in a deal valued at $1.25 billion upfront, with the potential…
Read More...

Owkin and Sanofi have announced a new multi-year collaboration aimed at accelerating drug discovery and development through advanced artificial intelligence technologies. The agreement…
Read More...

Novo Nordisk has announced that its oral obesity treatment, Wegovy® (semaglutide) tablets 25 mg, has surpassed three million prescriptions in the United States within just over five…
Read More...

Alnylam Pharmaceuticals and Inceptive Nucleics have entered into a strategic collaboration valued at up to $2 billion aimed at accelerating the development of next-generation RNA-based…
Read More...

Lonza and Stipple Bio have entered into a multi-target licensing agreement aimed at accelerating the development of next-generation antibody-drug conjugate (ADC) therapies for cancer,…
Read More...

Biogen has received a significant regulatory boost for its investigational spinal muscular atrophy (SMA) therapy salanersen after the U.S. Food and Drug Administration (FDA) granted the…
Read More...

Chai Discovery has entered into a licensing agreement with pharmaceutical giant Pfizer, marking a significant step in the growing adoption of artificial intelligence technologies across…
Read More...

Cellares and TScan Therapeutics have entered into a strategic agreement to evaluate automated clinical manufacturing of TSC-101, an investigational T cell receptor-engineered T cell…
Read More...